$-0.43 EPS Expected for aTyr Pharma, Inc. (LIFE)

March 8, 2018 - By Dolores Ford

 $ 0.43 EPS Expected for aTyr Pharma, Inc. (LIFE)

Analysts expect aTyr Pharma, Inc. (NASDAQ:LIFE) to report $-0.43 EPS on March, 15.They anticipate $0.10 EPS change or 18.87 % from last quarter’s $-0.53 EPS. After having $-0.43 EPS previously, aTyr Pharma, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.67% or $0.05 during the last trading session, reaching $3.05. About 1,325 shares traded. aTyr Pharma, Inc. (NASDAQ:LIFE) has risen 12.96% since March 8, 2017 and is uptrending. It has underperformed by 3.74% the S&P500.

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

Among 7 analysts covering Life Technologies Corp (NASDAQ:LIFE), 1 have Buy rating, 3 Sell and 3 Hold. Therefore 14% are positive. Life Technologies Corp had 13 analyst reports since August 25, 2015 according to SRatingsIntel. JP Morgan downgraded aTyr Pharma, Inc. (NASDAQ:LIFE) on Wednesday, February 14 to “Underweight” rating. The rating was initiated by Piper Jaffray with “Buy” on Thursday, September 7. The rating was downgraded by William Blair to “Market Perform” on Thursday, March 31. The company was initiated on Wednesday, December 16 by Citigroup. As per Wednesday, December 14, the company rating was downgraded by JP Morgan. The stock has “Hold” rating by BMO Capital Markets on Wednesday, November 1. BMO Capital Markets maintained the stock with “Hold” rating in Monday, August 14 report. As per Thursday, September 17, the company rating was downgraded by Zacks. The rating was maintained by Citigroup with “Neutral” on Tuesday, August 16. The rating was downgraded by J.P. Morgan on Wednesday, February 14 to “Sell”.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $90.76 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

More notable recent aTyr Pharma, Inc. (NASDAQ:LIFE) news were published by: Prnewswire.com which released: “aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results” on March 16, 2017, also Globenewswire.com with their article: “aTyr Pharma Announces First Quarter 2017 Operating Results” published on May 11, 2017, Prnewswire.com published: “aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors” on April 03, 2017. More interesting news about aTyr Pharma, Inc. (NASDAQ:LIFE) were released by: Globenewswire.com and their article: “aTyr Pharma to Present at Two Upcoming Investor Conferences in March” published on March 01, 2018 as well as Globenewswire.com‘s news article titled: “aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial …” with publication date: March 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.